Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).


CLL is a blood and bone ma"...



Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Dacogen (decitabine injection) and for I month afterwards, and to use effective contraception during this time, [See WARNINGS AND PRECAUTIONS].

Men should be advised not to father a child while receiving treatment with Dacogen (decitabine injection) , and for 2 months afterwards. During these times, men with female partners of childbearing potential should use effective contraception [See WARNINGS AND PRECAUTIONS and Nonclinical Toxicology].

Patients should be advised to monitor and report any symptoms of neutropenia, thrombocytopenia, or fever to their physician as soon as possible [See WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 4/1/2010
This monograph has been modified to include the generic and brand name in many instances.


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.